XNK Therapeutics has announced plans to further expand the scope of its technology platform of natural killer (NK) cell therapies outside of multiple myeloma to also include other cancer indications to broaden the pipeline.
The company will begin the preclinical and commercial work to expand the pipeline and expects to announce a decision in Q1 2022, it states.
An ideal time
“Our effort to treat multiple myeloma is progressing with our primary candidate drug just entering into a phase 2 study, making it the ideal time for the company to broaden its pipeline to include other cancer indications and fully leverage our expertise in NK cell-therapy,” says Johan Liwing, CEO of XNK Therapeutics.
XNK has announced promising clinical data in multiple myeloma and the scientific rationale for applying XNK’s technology in other indications, including solid cancers, is strong, the company states.